TheEdgeResearch
Home / Stocks / AUSAF

Australis Capital Inc. (AUSAF)

OTC Healthcare Drug Manufacturers - Specialty & Generic
$0.00 ▲ +0.00%
Market Cap
$2,783
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
-0.34
52-Wk Range
0.000001-0.001
CEO
Terrance R. Booth
Country
US
Currency
USD

Australis Capital Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Las Vegas, NV, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $2,783. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -661.5%. Its beta of -0.34 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-0.00
Price / Sales
0.00
Price / Book
0.00
EV / EBITDA
-0.13
Gross margin
52.4%
Operating margin
-256.0%
Net margin
-661.5%
Return on equity
—
Debt / equity
0.12
Current ratio
0.69
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
18
IPO date
2018-09-28
Headquarters
Las Vegas, NV, US
About Australis Capital Inc.

Australis Capital Inc. functions as a cannabis enterprise, actively pursuing both cannabis and horticultural ventures. These projects span a broad international landscape, encompassing the United States, Canada, Denmark, Finland, Iceland, Germany, the Netherlands, Bahrain, the United Arab Emirates, Southeast Asia, Australia, and numerous other global territories. The firm's corporate offices are located in Las Vegas, Nevada.

Comparable companies

Australis Capital Inc. is most often compared with the following Healthcare names:

AYRWFBUDZCBIHDHBUFFAGIHYEXIONKFLOBEFRPNRFTWSI
More research on AUSAF
AUSAF technical analysis AUSAF TheEdge Score Compare against peers
Open full interactive analysis & DCF →